<?xml version='1.0' encoding='utf-8'?>
<document id="15138710"><sentence text="Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects."><entity charOffset="36-48" id="DDI-PubMed.15138710.s1.e0" text="ketoconazole" /><entity charOffset="53-70" id="DDI-PubMed.15138710.s1.e1" text="imatinib mesylate" /><pair ddi="false" e1="DDI-PubMed.15138710.s1.e0" e2="DDI-PubMed.15138710.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15138710.s1.e0" e2="DDI-PubMed.15138710.s1.e1" /></sentence><sentence text="The study under discussion was a drug-drug interaction study in which the effect of ketoconazole, a potent CYP450 3A4 inhibitor, on the pharmacokinetics of Glivec (imatinib) was investigated"><entity charOffset="84-96" id="DDI-PubMed.15138710.s2.e0" text="ketoconazole" /><entity charOffset="164-172" id="DDI-PubMed.15138710.s2.e1" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.15138710.s2.e0" e2="DDI-PubMed.15138710.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15138710.s2.e0" e2="DDI-PubMed.15138710.s2.e1" /></sentence><sentence text=" A total of 14 healthy subjects (13 male, 1 female) were enrolled in this study" /><sentence text=" Each subject received a single oral dose of imatinib 200 mg alone, and a single oral dose of imatinib 200 mg coadministered with a single oral dose of ketoconazole 400 mg according to a two-period crossover design"><entity charOffset="45-53" id="DDI-PubMed.15138710.s4.e0" text="imatinib" /><entity charOffset="94-102" id="DDI-PubMed.15138710.s4.e1" text="imatinib" /><entity charOffset="152-164" id="DDI-PubMed.15138710.s4.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.15138710.s4.e0" e2="DDI-PubMed.15138710.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15138710.s4.e0" e2="DDI-PubMed.15138710.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s4.e0" e2="DDI-PubMed.15138710.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15138710.s4.e1" e2="DDI-PubMed.15138710.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s4.e1" e2="DDI-PubMed.15138710.s4.e2" /></sentence><sentence text=" The treatment sequence was randomly allocated" /><sentence text=" Subtherapeutic imatinib doses and a short exposure were tested in order not to overexpose the healthy volunteers"><entity charOffset="16-24" id="DDI-PubMed.15138710.s6.e0" text="imatinib" /></sentence><sentence text=" There was a minimum 7-day washout period between the two sequences" /><sentence text=" Blood samples for determination of plasma concentrations were taken up to 96 h after dosing" /><sentence text=" Imatinib and CGP74588 (main metabolite of imatinib) concentrations were measured using LC/MS/MS method and pharmacokinetic parameters were estimated by a non-compartmental analysis"><entity charOffset="1-9" id="DDI-PubMed.15138710.s9.e0" text="Imatinib" /><entity charOffset="14-22" id="DDI-PubMed.15138710.s9.e1" text="CGP74588" /><entity charOffset="43-51" id="DDI-PubMed.15138710.s9.e2" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.15138710.s9.e0" e2="DDI-PubMed.15138710.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15138710.s9.e0" e2="DDI-PubMed.15138710.s9.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s9.e0" e2="DDI-PubMed.15138710.s9.e2" /><pair ddi="false" e1="DDI-PubMed.15138710.s9.e1" e2="DDI-PubMed.15138710.s9.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s9.e1" e2="DDI-PubMed.15138710.s9.e2" /></sentence><sentence text=" Following ketoconazole coadministration, the mean imatinib C(max), AUC((0-24)) and AUC((0- infinity )) increased significantly by 26% ( P&lt;0"><entity charOffset="11-23" id="DDI-PubMed.15138710.s10.e0" text="ketoconazole" /><entity charOffset="51-66" id="DDI-PubMed.15138710.s10.e1" text="imatinib C(max)" /><entity charOffset="68-79" id="DDI-PubMed.15138710.s10.e2" text="AUC((0-24))" /><pair ddi="false" e1="DDI-PubMed.15138710.s10.e0" e2="DDI-PubMed.15138710.s10.e0" /><pair ddi="false" e1="DDI-PubMed.15138710.s10.e0" e2="DDI-PubMed.15138710.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s10.e0" e2="DDI-PubMed.15138710.s10.e2" /><pair ddi="false" e1="DDI-PubMed.15138710.s10.e1" e2="DDI-PubMed.15138710.s10.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s10.e1" e2="DDI-PubMed.15138710.s10.e2" /></sentence><sentence text="005), 40% ( P&lt;0" /><sentence text="0005) and 40% ( P &lt;0" /><sentence text="0005), respectively" /><sentence text=" There was a statistically significant decrease in apparent clearance (CL/f) of imatinib with a mean reduction of 28"><entity charOffset="80-88" id="DDI-PubMed.15138710.s14.e0" text="imatinib" /></sentence><sentence text="6% ( P&lt;0" /><sentence text="0005)" /><sentence text=" The mean C(max) and AUC((0-24)) of the metabolite CGP74588 decreased significantly by 22" /><sentence text="6% ( P&lt;0" /><sentence text="005) and 13% ( P&lt;0" /><sentence text="05) after ketoconazole treatment, although the AUC((0- infinity )) of CGP74588 only decreased by 5% ( P=0"><entity charOffset="10-22" id="DDI-PubMed.15138710.s20.e0" text="ketoconazole" /></sentence><sentence text="28)" /><sentence text=" Coadministration of ketoconazole and imatinib caused a 40% increase in exposure to imatinib in healthy volunteers"><entity charOffset="21-33" id="DDI-PubMed.15138710.s22.e0" text="ketoconazole" /><entity charOffset="38-46" id="DDI-PubMed.15138710.s22.e1" text="imatinib" /><entity charOffset="84-92" id="DDI-PubMed.15138710.s22.e2" text="imatinib" /><pair ddi="false" e1="DDI-PubMed.15138710.s22.e0" e2="DDI-PubMed.15138710.s22.e0" /><pair ddi="false" e1="DDI-PubMed.15138710.s22.e0" e2="DDI-PubMed.15138710.s22.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s22.e0" e2="DDI-PubMed.15138710.s22.e2" /><pair ddi="false" e1="DDI-PubMed.15138710.s22.e1" e2="DDI-PubMed.15138710.s22.e1" /><pair ddi="false" e1="DDI-PubMed.15138710.s22.e1" e2="DDI-PubMed.15138710.s22.e2" /></sentence><sentence text=" Given its previously demonstrated safety profile, this increased exposure to imatinib is likely to be clinically significant only at high doses"><entity charOffset="78-86" id="DDI-PubMed.15138710.s23.e0" text="imatinib" /></sentence><sentence text=" This interaction should be considered when administering inhibitors of the CYP3A family in combination with imatinib"><entity charOffset="109-117" id="DDI-PubMed.15138710.s24.e0" text="imatinib" /></sentence><sentence text="" /></document>